Hims & Hers Health, Inc. (NYSE: HIMS) is in the spotlight today after officially rolling out its new “Labs” diagnostic platform in partnership with Quest Diagnostics, even as the stock trades sharply lower and Wall Street sentiment turns more cautious. The telehealth company is trying to push deeper into preventive, data-led healthcare at the same time investors are digesting rich valuations, insider selling and tighter 2025 guidance. [1]
HIMS stock today: price, move and context
As of early afternoon on Friday, November 14, 2025, Hims & Hers shares are:
- Trading around $36.05
- Down roughly 7–8% on the day from a prior close near $39 [2]
- Giving the company an estimated market capitalization of about $8.2 billion, based on roughly 227.7 million shares outstanding [3]
- Still up about 43% year-to-date, despite the recent pullback [4]
- Trading well below its 52‑week high of $72.98, but comfortably above its low of $19.15 [5]
Trading has been volatile around HIMS in recent sessions, with options markets pricing in big swings and short-term expected moves of roughly 5% either way into this week’s options expiry. [6]
New ‘Labs’ hub pushes Hims & Hers deeper into preventive care
The biggest strategic announcement around Hims & Hers this week is the formal launch of Hims & Hers Labs, a new in-depth testing and health-monitoring service designed to give customers a more complete view of their long‑term health. [7]
Key points of the Labs rollout:
- Partnership with Quest Diagnostics:
Labs is being rolled out nationwide via a partnership with Quest Diagnostics, giving Hims & Hers customers access to blood testing at more than 1,000 Quest locations across the United States. [8] - Two subscription tiers:
According to Dow Jones and GuruFocus summaries of the launch, Labs offers two annual plans:- Base plan – $199/year: one blood draw covering roughly 50 biomarker tests
- Advanced plan – $499/year: two blood draws and around 120 biomarker tests across about 10 health categories [9]
- What gets tested:
The program focuses on markers linked to heart health, metabolism, hormones, inflammation and stress, with results tracked over time so customers can see trends rather than just one-off numbers. [10] - How it works for patients:
After visiting a Quest location for the blood draw, users receive results inside the Hims & Hers platform, along with doctor-developed action plans that may include lifestyle changes, supplements, prescription therapies or nutrition guidance where medically appropriate. [11] - Roadmap and ambition:
Management says Labs should make the platform more “intelligent” for clinicians and plans future expansion into at‑home testing devices, additional biomarker panels for areas like bone and brain health, and more advanced diagnostics aimed at chronic and serious disease detection. [12]
CEO Andrew Dudum has framed Labs as a way to make data-driven preventive care accessible at a price point most Americans can afford, and has suggested the offering could ultimately grow into a $1 billion business line if adoption scales. [13]
The launch builds on Hims & Hers’ existing portfolio in hair loss, mental health, dermatology, sexual health and GLP‑1 weight-loss treatments, where the company recently rolled out new features like Klarna financing options, shorter shipping intervals and micro‑dosing protocols to make obesity care more flexible for consumers. [14]
Strong Q3 growth meets higher scrutiny
Today’s trading action doesn’t come out of nowhere. Hims & Hers reported third-quarter 2025 earnings on November 3 and, on the surface, delivered another quarter of standout growth: [15]
- Q3 2025 revenue: about $599 million, up 49% year-over-year
- Online revenue: up roughly 50% YoY to $589.1 million
- Subscribers: about 2.47 million, up 21% YoY
- Net income: nearly $15.8 million
- Adjusted EBITDA: around $78.4 million, up over 50% YoY
- Gross margin: about 74%, down modestly from 79% a year ago
The company also narrowed full‑year 2025 guidance, now expecting revenue between $2.335 billion and $2.355 billion and adjusted EBITDA between $307–317 million. That midpoint revenue guide is roughly $5 million lower than prior expectations, even though Q3 itself beat Street estimates on revenue, EBITDA and EPS by low double‑digit percentages in some cases. [16]
That combination—rapid growth but tighter guidance—has left some investors questioning how long Hims & Hers can sustain 40–50% top‑line expansion while also pushing deeper into profitability.
Why HIMS shares are sliding today
Fresh commentary from TipRanks today highlights why sentiment has cooled even as the company launches flashy new services like Labs: [17]
- HIMS is experiencing a “significant drop” in its share price as at least one analyst issues a Sell rating, arguing the stock looks overvalued relative to its growth outlook.
- There are concerns about the sustainability of user growth and engagement, despite efforts to broaden the platform with Labs and enhanced GLP‑1 offerings.
- Ongoing insider selling and debate over Hims & Hers’ exposure to a small number of blockbuster products are contributing to a more cautious stance.
Data from GuruFocus and MarketBeat show how rich the valuation has become: [18]
- P/E ratio: around 67x
- Price-to-sales: roughly 4x
- Beta: over 2, and some sources peg stock volatility even higher
- 14‑day RSI: near 32, suggesting shares are approaching “oversold” territory in the short term
- Institutional ownership: about 63–78%, depending on the data provider
Meanwhile, MarketBeat notes the stock now carries a consensus rating of “Reduce” from Wall Street, with an average analyst price target around $45.27, still above today’s ~$36 quote but well below the stock’s 2025 highs. [19]
In other words: Hims & Hers is still priced as a high‑growth story, and any hint of slowing momentum or execution risk is being punished quickly.
Institutional flows and insider selling: mixed signals
Today also brought two notable institutional ownership updates via new 13F filing coverage: [20]
- Envestnet Asset Management
- Boosted its HIMS position by 41.8% in Q2
- Now holds 83,844 shares, valued at about $4.18 million at the time of filing
- Joins other large investors such as Nuveen, CloudAlpha, Jump Financial, Northern Trust and Corebridge Financial, all of which have recently built or increased stakes in Hims & Hers
- Mitsubishi UFJ Asset Management
- Cut its stake by 24.4% in Q2
- Sold 13,743 shares, leaving it with 42,564 shares worth roughly $2.12 million
Those moves underscore a split institutional view: some funds are leaning in aggressively, while others are trimming exposure after the stock’s big multi‑year run.
On the insider front, recent filings show meaningful selling activity: [21]
- CFO Oluyemi (Yemi) Okupe and CEO Andrew Dudum each sold sizable blocks of stock in recent months.
- MarketBeat estimates that insiders have sold more than 700,000 shares over the last quarter, worth roughly $37.6 million, even though insiders still hold about 13.7% of the company.
Insiders sell for many reasons—taxes, diversification, personal liquidity—but with valuations stretched, markets are reading these sales as one more reason to be careful.
Can Labs and GLP‑1 momentum offset growing doubts?
From a business standpoint, Labs is a logical next step:
- It deepens Hims & Hers’ shift from being known primarily as a hair‑loss and ED brand to a broader preventive and longitudinal health platform. [22]
- Subscription‑style diagnostics create new opportunities for cross‑selling into weight loss, dermatology, mental health and sexual health treatments.
- More lab data can strengthen the company’s ability to personalize care, potentially boosting retention and average revenue per subscriber—already up to about $80 per month versus $67 a year ago. [23]
However, several analysts and commentators—particularly in European investor media—argue that Hims & Hers is at a critical inflection point: either the new diagnostic and GLP‑1 initiatives successfully reignite momentum and justify the premium multiple, or the stock’s recent downtrend could deepen if growth slows or regulatory risks rise. [24]
In addition, recent research notes have flagged:
- Short interest in HIMS hovering near historically elevated levels, indicating that many traders remain skeptical. [25]
- Options activity that suggests investors are actively positioning for large price moves in the near term. [26]
Taken together, the picture is of a company executing well on revenue growth and product innovation, but operating under the bright spotlight of high expectations.
What today’s news means for investors and followers of HIMS
For anyone tracking Hims & Hers—whether as an investor, competitor, or just a follower of digital health—today’s developments boil down to a few big themes:
- Strategic expansion is real, not just hype.
- Labs + Quest Diagnostics give Hims & Hers a tangible foothold in preventive diagnostics, with clear pricing and nationwide reach from day one. [27]
- Growth is strong, but the bar is higher now.
- 49% revenue growth and 21% subscriber growth are impressive, yet the market is laser‑focused on margins, guidance and sustainability. [28]
- Valuation and sentiment are the main pressure points.
- A mid‑60s P/E, elevated volatility, insider selling and a “Reduce” consensus rating all add up to a more cautious Wall Street backdrop, even as price targets still sit above current levels. [29]
- Institutional and options positioning show both risk and opportunity.
- Big funds like Envestnet are buying more, others like Mitsubishi UFJ are trimming, and options traders are clearly bracing for large swings. [30]
As always, this coverage is for information and news purposes only and does not constitute investment advice. Anyone considering HIMS stock should look at their own risk tolerance, time horizon and financial situation, and, if needed, consult a qualified financial professional.
References
1. investors.hims.com, 2. www.marketbeat.com, 3. www.gurufocus.com, 4. www.tipranks.com, 5. www.marketbeat.com, 6. optioncharts.io, 7. investors.hims.com, 8. m.au.investing.com, 9. m.au.investing.com, 10. investors.hims.com, 11. investors.hims.com, 12. investors.hims.com, 13. m.au.investing.com, 14. stocktwits.com, 15. investors.hims.com, 16. investors.hims.com, 17. www.tipranks.com, 18. www.gurufocus.com, 19. www.marketbeat.com, 20. www.marketbeat.com, 21. www.marketbeat.com, 22. www.gurufocus.com, 23. investors.hims.com, 24. www.ad-hoc-news.de, 25. www.marketbeat.com, 26. news.futunn.com, 27. m.au.investing.com, 28. investors.hims.com, 29. www.marketbeat.com, 30. www.marketbeat.com
